Emicizumab-kxwh: First Global Approval
- 767 Downloads
Emicizumab-kxwh (Hemlibra®) is a bispecific humanized monoclonal antibody that restores the function of missing activated FVIII by bridging activated FIX and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab-kxwh is approved in the USA for use as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and paediatric patients with haemophilia A (congenital FVIII deficiency) with FVIII inhibitors. Subcutaneous emicizumab-kxwh is awaiting approval in several countries worldwide, including in the EU and Japan, and is undergoing phase 3 development in haemophilia A without FVIII inhibitors. This article summarizes the milestones in the development of emicizumab-kxwh leading to its first global approval for use as prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott and Esther Kim are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/4FFCF0605E76CF9D.
- 1.Adis Insight. Drug profile: emicizumab-kxwh. 2017. http://adis.springer.com/. Accessed 4 Dec 2017.
- 5.Genentech Inc. HEMLIBRA® (emicizumab-kxwh) injection: US prescribing information. 2017. http://www.fda.gov. Accessed 4 Dec 2017.
- 6.US FDA. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors [media release]. http://www.fda.gov. 16 Nov 2017.
- 12.Adamkewicz J, Schmitt C, Calatzis A, et al. Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 emicizumab (ACE910) phase 3 study [abstract no. OC 47.1]. In: International Society on Thrombosis and Haemostasis Conference. 2017.Google Scholar
- 15.Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors [abstract no. 85]. In: ASH 59th Annual Meeting and Exposition. 2017.Google Scholar
- 16.Young G, Oldenburg J, Liesner R, et al. Efficacy, safety and pharmacokinetics (PK) of once-weekly prophylactic (Px) emicizumab (ACE910) in pediatric (< 12 years) persons with hemophilia A with inhibitors (PwHAwI): interim analysis of single-arm, multicenter, open-label, phase 3 study (HAVEN 2) [abstract no. OC 24.1]. Res Pract Thromb Haemost. 2017;1(Suppl 1):5.Google Scholar